2017 Help me understand this report
The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic
Abstract: burden. Additional measures such as judicious use of investigations and optimizing outpatient treatment are required to ensure treatment access in the absence of widespread medical insurance.
This publication either has no citations yet, or we are still processing them
Set email alert for when this publication receives citations?
See others like this or search for similar articles
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
